OVIBIO is a biotechnology company with a mission to develop next-generation medicines for the prevention and treatment of life-limiting diseases associated with aging. Our approach leverages the remarkable natural systems of the human body to regulate the aging process and fight against disease. Our primary drug development program focuses on regulatory systems of longevity that have been shown to powerfully inhibit age-associated disease progression. Using state-of-the-art multidisciplinary approaches, our goal is to recapitulate critical components of this system engineered into novel bioavailable therapies that can change lives.
- Douglas Eby Co-Founder & CEO
- Alan Ashworth, PhD Co-Founder & Scientific Advisory Board Chairman
- Irene Chong, PhD Co-Founder
- Kenneth Lim, MD, PhD Co-Founder